99% Pharmaceutical Raw Material Oxcarbazepine Powder For Treatment Of Epilepsy
100G
MOQ
Negotiatable
Price
99% Pharmaceutical Raw Material Oxcarbazepine Powder For Treatment Of Epilepsy
Features Gallery Product Description Request A Quote
Features
Basic Infomation
Place of Origin: Wuhan,Hubei
Brand Name: Yuancheng
Certification: ISO9001
Model Number: 13803-74-2
High Light:

medicine raw material

,

raw materials testing pharmaceutical

Payment & Shipping Terms
Packaging Details: Discreet packaging
Delivery Time: 4-7working days
Payment Terms: T/T, , MoneyGram,Bitcoin
Supply Ability: 5000KG/Month
Specifications
Name: Oxcarbazepine
CAS: 28721-07-5
Molecular Formula: C15H12N2O2
Formula Weight: 252.27
Appearance: White Powder
Purity: 99%
Product Description

99% Pharmaceutical Raw Material Oxcarbazepine Powder For Treatment Of Epilepsy

Molecular Formula:C15H12N2O2
Formula Weight: 252.27
CAS No.:28721-07-5
Appearance:white powder
Purity:99%

Oxcarbazepine is an anticonvulsant drug primarily used in the treatment of epilepsy.There is some evidence for oxcarbazepine as a mood-stabilizing agent and thus, it can be used as add-on therapy for bipolar disorder in patients that have failed or are unable to tolerate approved treatments.

 

Oxcarbazepine is an anticonvulsant used to reduce the occurrence of epileptic episodes, and is not intended to cure epilepsy.Oxcarbazepine is used alone or in combination with other medications for the treatment of focal (partial) seizures in adults.In pediatric populations, it can be used by itself for the treatment of partial seizures for children 4 years and older, or in combination with other medications for children 2 years and older.

 

Patients receiving concomitant AEDs may be converted to monotherapy by initiating treatment with Oxcarbazepine at 600 mg/day (given in a twice-a-day regimen) while simultaneously initiating the reduction of the dose of the concomitant AEDs. The concomitant AEDs should be completely withdrawn over 3 to 6 weeks, while the maximum dose of Oxcarbazepine should be reached in about 2 to 4 weeks. Oxcarbazepine may be increased as clinically indicated by a maximum increment of 600 mg/day at approximately weekly intervals to achieve the recommended daily dose of 2400 mg/day. A daily dose of 1200 mg/day has been shown in one study to be effective in patients in whom monotherapy has been initiated with Oxcarbazepine. Patients should be observed closely during this transition phase.

Initiation of Monotherapy for Adults

 

Patients not currently being treated with AEDs may have monotherapy initiated with Oxcarbazepine. In these patients, Oxcarbazepine should be initiated at a dose of 600 mg/day (given in a twice-a-day regimen); the dose should be increased by 300 mg/day every third day to a dose of 1200 mg/day. Controlled trials in these patients examined the effectiveness of a 1200 mg/day dose; a dose of 2400 mg/day has been shown to be effective in patients converted from other AEDs to Oxcarbazepine monotherapy (see above).

 

The related products:

 

Pregabalin 148553-50-8
gabapentin 60142-96-3
Lamotrigine 84057-84-1
Levetiracetam 102767-28-2
brivaracetam 357336-20-0

 

Other hot products:

 

Nootropic Powder CAS#
Centrophenoxine 3685-84-5
Pramiracetam 68497-62-1,157115-85-0
Sunifiram 314728-85-3
Oxiracetam 62613-82-5
Aniracetam 72432-10-1
Fasoracetam 110958-19-5
Fasoracetam 135463-81-9
Fasoracetam 157115-85-0
Piracetam 7491-74-1
Sulbutiamine 3286-46-2
Tianeptine 66981-73-5
GTS-21 156223-05-1
Adrafinil 63547-13-7
Alpha-GPC 28319-77-9
 

 

99% Pharmaceutical Raw Material Oxcarbazepine Powder For Treatment Of Epilepsy 0

 

If you are interested in Oxcarbazepine ,please contact:
E-mail:nancypeng@ycphar.com
WhatsApp:86-15372437208
Skype:steroidsbio

 

Recommended Products
Get in touch with us
Contact Person : Lisa
Fax : 86-27-88508150-803
Characters Remaining(20/3000)